✦ LIBER ✦

52 Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib

✍ Scribed by U. Gatzemeier; J.Y. Douillard; M. Kris; M. Fukuoka; R. Herbst; J. Schiller; M. Wolf; A. McPartiane; A. Kay; A. Fandi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-615 Phase II trials of gefitinib (‘Ire

✍ Fukuoka, Masahiro; Kris, Mark; Giaccone, Giuseppe; Lynch, Thomas; Nakagawa, Kazu 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 379 KB

A phase I trial of gefitinib and nimotuz

✍ Kim, Se Hyun; Shim, Hyo Sup; Cho, Jaeho; Jeong, Jae Heon; Kim, Sun Mi; Hong, Yun 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 275 KB

ZD1839 (‘Iressa’) provides clinically si

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Phase II trial of sequential gefitinib a

✍ Jian Ming Xu; Yu Han; Yue Min Li; Chuan Hua Zhao; Yan Wang; Angelo Paradiso 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 261 KB

Gefitinib in Combination With Gemcitabin

✍ Giaccone, G. 📂 Article 📅 2004 🏛 American Society of Clinical Oncology 🌐 English ⚖ 430 KB

The EGFR mutation and its correlation wi

✍ Zhang, X.-T. 📂 Article 📅 2005 🏛 Oxford University Press 🌐 English ⚖ 301 KB